Best PT-141 Providers in 2026 — Ranked & Reviewed
Low sexual desire is the indication for PT-141 (bremelanotide). The mechanism is what separates it from the ED medications sold beside it: the central melanocortin pathway rather than blood flow. A prescription is required. A licensed clinician stands behind each provider below, and each is scored on our standard dimensions.
28 providers compared
New to PT-141? Read our full PT-141 guide — evidence, dosing, safety and side effects.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
28 pt-141 providers compared · independently scored against our six-factor methodology.
Compare the top providers at a glance
Every row carries a logo, our editorial rating, price, the medications prescribed, and where the seller ships. Scan down a column and the list shortens fast.
- ★ Editor's Pick
bloodwork inside the $99/month rather than billed on top
From /moCheck pricingCoverage36 statesMedicationsBPC-157GHK-CuGlutathioneGonadorelinkpvMOTS-cnad-plusPT-141retatrutideSermorelinTB-500Tesamorelin starting below a standard dose, with microdose tiers
From /moCheck pricingCoverage8 statesMedicationsGHK-CuGlutathioneNAD+PT-141SermorelinTB-500- Nationwide Coverage
starting below a standard dose, with microdose tiers
From /moCheck pricingCoverage50 statesMedicationsGHK-CuNAD+PT-141Sermorelin starting below a standard dose, with microdose tiers
From /moCheck pricingCoverageCheck intakeMedicationsBPC-157CJC-1295 / IpamorelinGHK-CuIpamorelinNAD+PT-141SermorelinTB-500semaglutide at $119/month, 37% under the register median
From /moCheck pricingCoverageCheck intakeMedicationsGonadorelinNAD+PT-141Sermorelinbloodwork inside the $149/month rather than billed on top
From /moCheck pricingCoverageCheck intakeMedicationsGlutathioneGonadorelinNAD+PT-141coverage in all 50 states, which most of the register will not confirm
From /moCheck pricingCoverage50 statesMedicationsGHK-CuGlutathioneNAD+PT-141Sermorelinan oral route if you will not self-inject
From /moCheck pricingCoverageCheck intakeMedicationsGlutathioneNAD+PT-141Sermorelin
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick bloodwork inside the $99/month rather than billed on top | Check pricing | BPC-157GHK-CuGlutathioneGonadorelinkpvMOTS-cnad-plusPT-141retatrutideSermorelinTB-500Tesamorelin | 36 states | Visit → | |
 starting below a standard dose, with microdose tiers | Check pricing | GHK-CuGlutathioneNAD+PT-141SermorelinTB-500 | 8 states | Visit → | |
Nationwide Coverage starting below a standard dose, with microdose tiers | Check pricing | GHK-CuNAD+PT-141Sermorelin | 50 states | Visit → | |
 starting below a standard dose, with microdose tiers | Check pricing | BPC-157CJC-1295 / IpamorelinGHK-CuIpamorelinNAD+PT-141SermorelinTB-500 | Check intake | Visit → | |
 semaglutide at $119/month, 37% under the register median | Check pricing | GonadorelinNAD+PT-141Sermorelin | Check intake | Visit → | |
 bloodwork inside the $149/month rather than billed on top | Check pricing | GlutathioneGonadorelinNAD+PT-141 | Check intake | Visit → | |
 coverage in all 50 states, which most of the register will not confirm | Check pricing | GHK-CuGlutathioneNAD+PT-141Sermorelin | 50 states | Visit → | |
 an oral route if you will not self-inject | Check pricing | GlutathioneNAD+PT-141Sermorelin | Check intake | Visit → |
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
Detailed Reviews
About the prices below: every dollar figure inside these provider summaries belongs to that clinic’s GLP‑1 weight-loss program. None is a PT-141 price. For PT-141 itself, read the figure next to each clinic in the comparison table above, taken from the clinic’s own product page. A reading of “Check pricing” means the clinic does prescribe PT-141 and publishes nothing for it, so you are quoted after your consultation.
Pepti
Best for: bloodwork inside the $99/month rather than billed on top
One flat charge holds regardless of dose: $99 a month for injectable semaglutide, $199 for tirzepatide, each figure covering shipping, refill management, baseline labs, physician review and the drug itself. Registered in Delaware, the platform reaches 36 states with doctor-prescribed compounded peptides and GLP-1s, and its catalog passes 120 products spanning skin, cognitive, recovery, TRT and hormone, and weight-loss categories, bloodwork at home included. Insurance is not billed. Pepti prescribes nothing itself; it is the platform.
Score Breakdown
Pros
- ✓Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- ✓The monthly figure covers medication, consult, shipping, labs
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗Coverage is published for 36 states only, so this may not reach you
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Onyx Weight Loss
Best for: starting below a standard dose, with microdose tiers
GLP-1 (semaglutide-type) plans begin at $228/month; GLP-1/GIP (tirzepatide-type) plans at $280/month. There is also a $99/month GLP-1 microdosing option for anyone wanting a gradual-titration start. Onyx Weight Loss runs a nurse-practitioner-led telehealth clinic out of Mooresville, NC, set up by Madalyn Vangile RN and Tasha Vangile FNP-C, and it covers 8 states with HRT and peptides sold beside the GLP-1s. Its partner Strive Pharmacy ships medication and supplies home.
Score Breakdown
Pros
- ✓Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓The monthly figure covers medication, consult, shipping
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗Coverage is published for 8 states only, so this may not reach you
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
PlexusDx
Best for: starting below a standard dose, with microdose tiers
PlexusDx (plexusdx.com) prices a microdose GLP-1 from $129/month, compounded semaglutide from $149/month and compounded tirzepatide from $249/month, and also sells a combination GLP-Squared protocol. An independent US-licensed clinician reviews each patient through a state-licensed telehealth platform, medications come from state-licensed pharmacies, and licensed providers cover all 50 states. What sets it apart is an optional Precision Peptide genetic test returning 151 insights, discounted to $99 after a first order.
Score Breakdown
Pros
- ✓Semaglutide at $129 a month, 32% below the $189 median for the same drug and form across this register
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓The monthly figure covers medication and consult
- ✓Coverage is published for all 50 states
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Telos Rx
Verified partnerBest for: starting below a standard dose, with microdose tiers
Read the $49 headline at Telos Rx carefully: it is a first-month intro rate and the standing cost sits above it. Superior Health Solutions LLC operates the platform, which sells GLP-1 weight loss beside longevity, recovery and sexual-health peptides. Compounded semaglutide and tirzepatide come as injections, or as needle-free sublinguals, with a microdosed tirzepatide too. Providers adjust doses, labs are monitored, delivery is free and discreet, FSA/HSA works and canceling is open. Compounded drugs are not FDA-approved. No pharmacy, no state list, no LegitScript.
Score Breakdown
Pros
- ✓Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- ✓Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓The monthly figure covers medication, consult, shipping
- ✓No FDA warning letter matched this operator when we searched our enforcement register
- ✓Both oral and injectable options are on record, so the format is a choice rather than a condition
Cons
- ✗No state list is on record here, so whether it serves your state cannot be confirmed from this page
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Try Ageless
Best for: semaglutide at $119/month, 37% under the register median
Semaglutide by injection opens at $119/month, about as low an entry price as we track anywhere, and aggressive introductory pricing runs across all five products. Three delivery formats exist for the compounded semaglutide and tirzepatide sold here: injection, troche, and drops placed under the tongue. Nobody else in our directory spans that many. The platform frames itself around longevity and metabolic health, and holds LegitScript certification.
Score Breakdown
Pros
- ✓Semaglutide at $119 a month, 37% below the $189 median for the same drug and form across this register
- ✓Tirzepatide at $169 a month, 37% below the $267 median for the same drug and form across this register
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓The monthly figure covers medication and shipping
- ✓No FDA warning letter matched this operator when we searched our enforcement register
- ✓Both oral and injectable options are on record, so the format is a choice rather than a condition
Cons
- ✗No state list is on record here, so whether it serves your state cannot be confirmed from this page
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Buying PT-141: approved product, or a compound
Bremelanotide, sold as PT-141, is the only molecule in this category holding a genuine FDA approval. That approval covers Vyleesi, in premenopausal women with hypoactive sexual desire disorder. What telehealth clinics mostly dispense is a compounded version, frequently to men, which uses an approved molecule off label.
What to check
- Vyleesi, or a compounded vial. An approved autoinjector and a compounded vial differ in price, in labeling, and in what has been approved about them. Which one a clinic dispenses is a single sentence it either publishes or leaves out.
- Dosed before activity, not daily. The dose goes in ahead of anticipated activity. No daily schedule exists for this molecule, so a clinic selling one has the model wrong.
- Blood pressure asked about. A transient rise in blood pressure, and a drop in heart rate, follow the dose. Uncontrolled hypertension and known cardiovascular disease are contraindications on that basis. An intake either asks about them or omits the main safety check in this category.
Red flags
- Vials sold with no prescriber involved. A vial marked 'not for human consumption' and sold 'for research use only' sits outside the drug approval system, where identity, purity and sterility are nobody's stated responsibility. In the US, every peptide on this page needs a prescription. Where no licensed clinician writes one, the product is not the one described here.
- The 503A or 503B pharmacy is never named. No finished product for these peptides carries FDA approval, which leaves compounding as the only lawful route to a dose. Plenty of clinics name the pharmacy behind the vial. Where a clinic does not, the supply chain ends at its own claim.
- 'FDA-approved' attached to a compounded peptide. Compounding does not bring FDA approval with it, and a seller saying otherwise has committed a marketing violation rather than a slip of wording. A few of these molecules did hold an approval once, under a discontinued brand and for a separate indication. That history says nothing about the compounded vial on sale now.
- Results promised with no trial behind them. For most molecules in this category the evidence is mechanistic or early phase; randomized outcome trials are rare. A clinic promising a defined outcome for fat loss, for muscle, or for anti-aging has moved past what the literature carries. Our evidence review for each molecule sets out what exists.
- IGF-1 never drawn on a hormone-axis peptide. Raising IGF-1 is what a growth-hormone secretagogue is for, and it is also the number that shows when a dose has gone too far. A clinic measuring it at neither baseline nor follow-up has no way to tell those two states apart.
Every seller listed above is scored on these criteria under our six-dimension methodology, with prices re-checked against the seller’s own live site.
How we rank, and what counts as “legit”
Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.
Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].
How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- 503A pharmacy · Pharmacy and drug forms
- 503A vs 503B (pharmacy compounding) · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.